Development and implementation of a new generation of hyaluronic acid for the vinification and regeneration of ponds. (Q78416): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Osteoarthritis is a common health problem and affects people of different ages.According to data from the World Health Organisation, it suffers from around60 %...) |
||
| Property / summary | |||
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Osteoarthritis is a common health problem and affects people of different ages.According to data from the World Health Organisation, it suffers from around60 % of men and 70 % of women over the age of 65.This number will increase exponentially in view of the constantly growing life expectancy.Osteoottism is a very onerous disease of & ndash;the consequence is joint pain, rigidity and mobility difficulties.This is due to the presence of inflammation and damage to the cartilage of the joint.The purpose of the project is to prepare the technology for the commercial implementation of a stabilised hyalonic acid, enriched with silicon, and lecithin, into the supply injection of an innovative product for vitellogenin.By using a combination of hyaluronic acid and lecithin it will be possible to complete the shortage of ponds and ensure that the joints of the joint panels are suitable.By contrast, the use of silicon compounds in the preparation inhibits the process of degradation and will start the processes associated with the regeneration of cartilage, which will have a significant impact on the comfort of patients’ lives.The product will be a landmark in the country and the world.The project is intended to accelerate the formulation of the formula and the testing of the performance of the final product and to carry out costly tests related to the creation of technological jerks.The project will increase the scale and manufacture of the pilot series to be used for the validation studies, pre-clinical and clinical trials.Technical documentation and registration documents will also be drawn up in a timely manner. (English) | |||
| Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Osteoarthritis is a common health problem and affects people of different ages.According to data from the World Health Organisation, it suffers from around60 % of men and 70 % of women over the age of 65.This number will increase exponentially in view of the constantly growing life expectancy.Osteoottism is a very onerous disease of & ndash;the consequence is joint pain, rigidity and mobility difficulties.This is due to the presence of inflammation and damage to the cartilage of the joint.The purpose of the project is to prepare the technology for the commercial implementation of a stabilised hyalonic acid, enriched with silicon, and lecithin, into the supply injection of an innovative product for vitellogenin.By using a combination of hyaluronic acid and lecithin it will be possible to complete the shortage of ponds and ensure that the joints of the joint panels are suitable.By contrast, the use of silicon compounds in the preparation inhibits the process of degradation and will start the processes associated with the regeneration of cartilage, which will have a significant impact on the comfort of patients’ lives.The product will be a landmark in the country and the world.The project is intended to accelerate the formulation of the formula and the testing of the performance of the final product and to carry out costly tests related to the creation of technological jerks.The project will increase the scale and manufacture of the pilot series to be used for the validation studies, pre-clinical and clinical trials.Technical documentation and registration documents will also be drawn up in a timely manner. (English) / rank | |||
Normal rank | |||
Revision as of 09:10, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development and implementation of a new generation of hyaluronic acid for the vinification and regeneration of ponds. |
Project in Poland financed by DG Regio |
Statements
7,322,985.18 zloty
0 references
1,757,516.4431999999 Euro
0.24 Euro
13 January 2020
0 references
11,201,150.7 zloty
0 references
2,688,276.1679999996 Euro
0.24 Euro
13 January 2020
0 references
65.38 percent
0 references
2 January 2017
0 references
30 June 2020
0 references
BIOVICO SP. Z O. O.
0 references
54°30'13.7"N, 18°27'46.1"E
0 references
Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Choroba zwyrodnieniowa stawów (osteoartretyzm) jest powszechnym problemem zdrowotnym i dotyczy osób w różnym wieku. Według danych Światowej Organizacji Zdrowia cierpi na nią ok. 60% mężczyzn i 70% kobiet w wieku powyżej 65 lat. Liczba ta będzie wzrastać w sposób wykładniczy, ze względu na stale wydłużający się czas życia. Osteoartretyzm jest chorobą bardzo uciążliwą – jej konsekwencją jest ból stawów, ich zesztywnienie i trudności w poruszaniu się. Jest to związane z występowaniem stanu zapalnego oraz uszkodzeniami chrząstki stawu. Celem projektu jest przygotowanie technologii do komercyjnego wdrożenia stabilizowanego kwasu hialuronowego, wzbogaconego o związki krzemu oraz lecytynę, do iniekcji dostawowej stanowiący innowacyjny produkt do wiskosuplementacji. Dzięki zastosowaniu kombinacji kwasu hialuronowego oraz lecytyny możliwe będzie uzupełnienie niedoborów mazi stawowej oraz zapewnienie odpowiedniego efektu lubrykacyjnego panewek stawowych. Natomiast, wykorzystanie w preparacie związków krzemu zahamuje proces degradacji oraz uruchomi procesy związane z regeneracją chrząstki, co istotnie wpłynie na komfort życia pacjentów. Opracowany produkt będzie przełomowy w skali kraju oraz świata. W ramach projektu planowane jest przyśpieszenie optymalizacji formulacji oraz badań efektywności działania końcowego produktu oraz przeprowadzenie kosztownych badań związanych z wytworzeniem szarż technologicznych. W ramach projektu przeprowadzone zostanie podniesienie skali i wytworzenie serii pilotażowych, które zostaną wykorzystane do badań walidacyjnych, przedklinicznych oraz klinicznych. Opracowana zostanie również dokumentacja technologiczna i rejestracyjna pozwalająca na szybkie (Polish)
0 references
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).Osteoarthritis is a common health problem and affects people of different ages.According to data from the World Health Organisation, it suffers from around60 % of men and 70 % of women over the age of 65.This number will increase exponentially in view of the constantly growing life expectancy.Osteoottism is a very onerous disease of & ndash;the consequence is joint pain, rigidity and mobility difficulties.This is due to the presence of inflammation and damage to the cartilage of the joint.The purpose of the project is to prepare the technology for the commercial implementation of a stabilised hyalonic acid, enriched with silicon, and lecithin, into the supply injection of an innovative product for vitellogenin.By using a combination of hyaluronic acid and lecithin it will be possible to complete the shortage of ponds and ensure that the joints of the joint panels are suitable.By contrast, the use of silicon compounds in the preparation inhibits the process of degradation and will start the processes associated with the regeneration of cartilage, which will have a significant impact on the comfort of patients’ lives.The product will be a landmark in the country and the world.The project is intended to accelerate the formulation of the formula and the testing of the performance of the final product and to carry out costly tests related to the creation of technological jerks.The project will increase the scale and manufacture of the pilot series to be used for the validation studies, pre-clinical and clinical trials.Technical documentation and registration documents will also be drawn up in a timely manner. (English)
0 references
Identifiers
POIR.01.01.01-00-0864/16
0 references